# FDA 483 - Intas Pharmaceuticals Limited - February 28, 2020

Source: https://www.keypedia.com/records/483/intas-pharmaceuticals-limited/4840cbe4-0699-45d1-b557-35037fad9e93

> FDA 483 for Intas Pharmaceuticals Limited on February 28, 2020. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Intas Pharmaceuticals Limited
- Inspection Date: 2020-02-28
- Product Type: drugs
- Office Name: Office of Biological Products Operations - Division I
- Summary: An FDA inspection of Intas Pharmaceuticals Limited in Ahmedabad, India, revealed significant deficiencies in their quality control unit. The firm failed to ensure process validation for packaging was completed and approved before distributing drug batches to the US market. Additionally, the Quality Assurance unit did not conduct required manufacturing investigations following confirmed out-of-specification results for impurities in stability testing.

## Related Documents

- [483 - 2019-05-28](https://www.keypedia.com/records/483/intas-pharmaceuticals-limited/ce617d78-cad5-4a6b-9b44-9d98421912d8)
- [483 - 2022-12-02](https://www.keypedia.com/records/483/intas-pharmaceuticals-limited/51f72db3-f323-4bb3-9458-0baa02a1227d)
- [WARNING_LETTER - 2022-12-02](https://www.keypedia.com/records/warning_letter/intas-pharmaceuticals-limited/69e72c80-0677-41df-92b7-50c9a9d7402e)
- [WARNING_LETTER - 2023-05-12](https://www.keypedia.com/records/warning_letter/intas-pharmaceuticals-limited/9e0758c3-e43d-4af6-8f19-a85862cedff3)

## Related Officers

- [Jennifer L. Huntington](https://www.keypedia.com/people/jennifer-l-huntington/c04e1c86-c7ec-4613-b3f7-a1f9ba2b2f2c)

Company: https://www.keypedia.com/companies/intas-pharmaceuticals-limited/cfedbb2f-5587-42dc-985b-044083dd01e5

Office: https://www.keypedia.com/offices/office-of-biological-products-operations-division-i/49c53dac-7724-4c8c-8708-4f5779ea69c1